
Opinion|Podcasts|August 4, 2025
B Cells as a Treatment Target in Myasthenia Gravis
Author(s)Ali Habib, MD, Arjun Seth, MD
Ali Habib, MD, and Arjun Seth, MD, discuss how B-cell–targeted therapies represent a promising upstream treatment approach for myasthenia gravis that could provide more sustained efficacy compared with current downstream treatments like complement inhibitors and FcRn antagonists, with CD19-targeting agents like inebilizumab showing particular promise in clinical trials for both acetylcholine receptor and MuSK antibody subtypes.
Advertisement
Time Codes
2:09 Pathophysiology of MG
6:32 Up/Downstream MG Targets
10:26 Recent Approvals in MG
14:20 B-Cell Targets in MG
17:07 Inebilizumab in MG
19:55 Anti-CD19 Targets in MG
23:11 Safety of MG Therapies
25:26 Role of Targeted Tx in MG
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
2
Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease
3
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
4
This Week on NeurologyLive® — July 20, 2026
5

















